Clinical Validation

London – September 19, 2026 -- Business Worldwide Magazine has named MyPureSkin S.A, a Swiss nutricosmetics company, to its list of the 20 Most Innovative Healthcare Companies to Watch in 2026.

Swiss firm builds clinically validated skin-health platform from Health Valley base

Founded by Edgar Brandt and Tatiana Brandt in Switzerland's Health Valley, MyPureSkin operates on the premise that skin should receive the same nutritional and scientific attention as other organs. The company now sells across Europe, North America, the Middle East, and Australia.

Proprietary Nutrigevity framework anchors product development

MyPureSkin's formulations are built around NutrigevityTM, a proprietary framework targeting three biological pillars: Structure, Signalling, and Regeneration. The framework draws on expertise from clinical medicine, plastic surgery, gynaecology, micronutrition, and skin biology.

Houston – September 19, 2026 -- Octagos has been named to TIME and Statista's World's Top HealthTech Companies of 2026 list, marking the only cardiac implantable electronic device (CIED) monitoring company recognized in either the inaugural 2025 ranking or the 2026 edition.

TIME and Statista rank Octagos among 82 AI and Data Analytics firms out of 500 global honorees

The evaluation weighted financial performance at 50%, reputation at 30%, and online engagement at 20%. Octagos received a "Very High" performance rating within the AI and Data Analytics category, one of six categories spanning the 500-company list.

Lexington, S.C. – September 13, 2026 -- ElectroWire Medical's FDA-cleared LightningWire Transseptal Puncture System has completed its first six clinical cases at Spartanburg Medical Center in Spartanburg, South Carolina, with zero complications reported.

Six procedures spanned mitral repair, LAA occlusion and pulsed field ablation

The case mix included one mitral valve repair, one left atrial appendage occlusion, and four pulsed field ablations, performed by structural interventional cardiologist Dr. Nalin Srivastava and cardiac electrophysiologist Dr. David Rodak. The team used four different transseptal introducers and two different electrosurgical generators during the cases, testing the device's compatibility with equipment already in operator inventories.